Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：80

作者：

Boucau, Julie ^{[1
]}

Uddin, Rockib ^{[2
]}

Marino, Caitlin ^{[1
]}

Regan, James ^{[3
]}

Flynn, James P. ^{[3
]}

Choudhary, Manish C. ^{[3
,4
]}

Chen, Geoffrey ^{[2
]}

Stuckwisch, Ashley M. ^{[2
]}

Mathews, Josh ^{[2
]}

Liew, May Y. ^{[2
]}

Singh, Arshdeep ^{[2
]}

Reynolds, Zahra ^{[2
]}

Iyer, Surabhi L. ^{[2
]}

Chamberlin, Grace C. ^{[2
]}

Vyas, Tammy D. ^{[2
]}

Vyas, Jatin M. ^{[2
,4
]}

Turbett, Sarah E. ^{[2
]}

Li, Jonathan Z. ^{[3
,4
]}

Lemieux, Jacob E. ^{[2
,4
,5
]}

Barczak, Amy K. ^{[1
,2
,4
]}

Siedner, Mark J. ^{[2
,4
]}

机构：

[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA

[2] Massachusetts Gen Hosp, Boston, MA 02215 USA

[3] Brigham & Womens Hosp, Boston, MA 02215 USA

[4] Harvard Med Sch, Boston, MA 02215 USA

[5] Broad Inst, Cambridge, MA 02138 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期

关键词：

COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;

D O I：

10.1093/cid/ciac512

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

引用

页码：E526 / E529

页数：4

共 50 条

[41] Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir-ritonavir in adult patients with COVID-19: A randomized,-label, multicenter trial [J].

Zou, Xiaohui ;

Chang, Kang ;

Fan, Guohui ;

Zheng, Huanwei ;

Shen, Hezheng ;

Tang, Liang ;

Yang, Yingying ;

Wang, Yeming ;

Zhao, Linhua ;

Lv, Hong ;

Zhou, Xin ;

Shen, Xiaoming ;

Chen, Liqiang ;

Tong, Xiaolin ;

Cao, Bin .

SCIENCE BULLETIN, 2024, 69 (12) :1954-1963

[42] Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study [J].

Qinqin Zhao ;

Bei Zheng ;

Bing Han ;

Pinpin Feng ;

Zhongni Xia ;

Hong Jiang ;

Yin Ying ;

Jun Zhu ;

Cheng Fei ;

Junlei Xiang ;

Lingli Shen ;

Qiliang Luo ;

Yinhuan Wu ;

Ayiguzhali Wusiman ;

Chuanwei Xin ;

Meiling Zhang ;

Gonghua Li ;

Xiang Li .

Infectious Diseases and Therapy, 2023, 12 :2087-2102

[43] Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study [J].

Zhao, Qinqin ;

Zheng, Bei ;

Han, Bing ;

Feng, Pinpin ;

Xia, Zhongni ;

Jiang, Hong ;

Ying, Yin ;

Zhu, Jun ;

Fei, Cheng ;

Xiang, Junlei ;

Shen, Lingli ;

Luo, Qiliang ;

Wu, Yinhuan ;

Wusiman, Ayiguzhali ;

Xin, Chuanwei ;

Zhang, Meiling ;

Li, Gonghua ;

Li, Xiang .

INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) :2087-2102

[44] Drug treatment of coronavirus disease 2019 (COVID-19) in China [J].

Jin, Zhe ;

Liu, Jing-Yi ;

Feng, Rang ;

Ji, Lu ;

Jin, Zi-Li ;

Li, Hai-Bo .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 883

[45] Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial [J].

Zhou, Yiling ;

Liu, Yi ;

Jiang, Li ;

Zhang, Renqing ;

Zhang, Huohuo ;

Shi, Qingyang ;

Yang, Zhirong ;

Mao, Yi ;

Liu, Sha ;

Yang, Zhibo ;

Ding, Jialin ;

Zhou, Yongzhao ;

Ren, Bi ;

He, Liping ;

Zhao, Xing ;

Li, Weimin ;

Li, Sheyu ;

Liu, Dan .

JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (12)

[46] COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease [J].

Dousari, Amin Sadeghi ;

Moghadam, Majid Taati ;

Satarzadeh, Naghmeh .

INFECTION AND DRUG RESISTANCE, 2020, 13 :2819-2828

[47] An overview on the role of antibiotic therapy in the treatment of Coronavirus disease 2019 (COVID-19) [J].

Afshar, Zeinab Mohseni ;

Sayad, Babak ;

Janbakhsh, Alireza ;

Ebrahimpour, Soheil ;

Babazadeh, Arefeh .

MINERVA RESPIRATORY MEDICINE, 2023, 62 (02) :83-88

[48] Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19 [J].

Reddy, Gangireddy Navitha ;

Jogvanshi, Akanksha ;

Naikwadi, Sana ;

Sonti, Rajesh .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (09) :943-955

[49] Comparison of safety and ef fi cacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study [J].

Chu, Wing Ming ;

Wan, Eric Yuk Fai ;

Wong, Zoey Cho Ting ;

Tam, Anthony Raymond ;

Wong, Ian Chi Kei ;

Chan, Esther Wai Yin ;

Hung, Ivan Fan Ngai .

ECLINICALMEDICINE, 2024, 72

[50] The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients [J].

Xiang, Zheng ;

Wang, Yueyuan ;

Qu, Yuchen ;

Lv, Bo ;

Han, Junping ;

Xu, Delai ;

Fan, Kai ;

Su, Cunjin ;

Shen, Zhu .

INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2024, 17

← 1 2 3 4 5 →